JO
NRIX icon

John Overdeck’s Nurix Therapeutics NRIX Stock Holding History

John Overdeck’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-62,875
Closed -$581K – 4303
2025
Q3 		$581K Sell
62,875
-95,849
-60% -$995K ﹤0.01% 2914
2025
Q2 		$1.81M Sell
158,724
-98,801
-38% -$1.07M ﹤0.01% 1910
2025
Q1 		$3.06M Buy
257,525
+122,441
+91% +$2.05M 0.01% 1442
2024
Q4 		$2.54M Buy
135,084
+84,375
+166% +$1.93M 0.01% 1555
2024
Q3 		$1.14M Sell
50,709
-10,179
-17% -$231K ﹤0.01% 2050
2024
Q2 		$1.27M Sell
60,888
-150,428
-71% -$2.34M ﹤0.01% 1855
2024
Q1 		$3.11M Buy
211,316
+116,544
+123% +$1.25M 0.01% 1213
2023
Q4 		$978K Buy
94,772
+68,015
+254% +$466K ﹤0.01% 2096
2023
Q3 		$210K Sell
26,757
-21,371
-44% -$195K ﹤0.01% 2625
2023
Q2 		$481K Buy
48,128
+36,828
+326% +$376K ﹤0.01% 2352
2023
Q1 		$100K Sell
11,300
-25,514
-69% -$266K ﹤0.01% 2672
2022
Q4 		$404K Buy
+36,814
New +$444K ﹤0.01% 2114
2022
Q2 		– Sell
-91,335
Closed -$1.28M – 2807
2022
Q1 		$1.28M Buy
+91,335
New +$1.62M ﹤0.01% 1581

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's NRIX Position: Q4 2025 in Review

John Overdeck sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 62,875 shares — an estimated $581K sold.

John Overdeck first reported a position in NRIX in Q1 2022 and held it in 13 quarters. The position peaked at $3.11M in Q1 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • John Overdeck reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • John Overdeck sold 62,875 Nurix Therapeutics shares in Q4 2025, an estimated $581K.
  • John Overdeck first reported a position in Nurix Therapeutics in Q1 2022 and held it in 13 quarters.
  • John Overdeck's Nurix Therapeutics position peaked at $3.11M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Two Sigma Investments's 13F filing for Q4 2025, filed 17 Feb 2026.